Charles Schwab Investment Management Inc. Buys 179,600 Shares of Envista Holdings Co. (NYSE:NVST)

Charles Schwab Investment Management Inc. raised its stake in Envista Holdings Co. (NYSE:NVST) by 8.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,317,631 shares of the company’s stock after acquiring an additional 179,600 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.35% of Envista worth $44,707,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVST. US Bancorp DE lifted its position in shares of Envista by 150.6% during the third quarter. US Bancorp DE now owns 4,971 shares of the company’s stock worth $98,000 after acquiring an additional 2,987 shares in the last quarter. Assetmark Inc. raised its stake in shares of Envista by 5.9% during the 3rd quarter. Assetmark Inc. now owns 38,641 shares of the company’s stock valued at $764,000 after purchasing an additional 2,152 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Envista by 5.4% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 107,686 shares of the company’s stock worth $2,128,000 after purchasing an additional 5,497 shares in the last quarter. Huntington National Bank boosted its stake in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after purchasing an additional 949 shares during the period. Finally, Royce & Associates LP grew its holdings in Envista by 6.3% during the 3rd quarter. Royce & Associates LP now owns 278,904 shares of the company’s stock valued at $5,511,000 after buying an additional 16,547 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Morgan Stanley cut their price target on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 price objective on Envista in a research note on Saturday, March 8th. JPMorgan Chase & Co. decreased their target price on Envista from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Mizuho assumed coverage on Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Envista currently has a consensus rating of “Hold” and an average price target of $20.18.

Envista Stock Up 2.3 %

NVST stock opened at $16.63 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. Envista Holdings Co. has a 1-year low of $15.15 and a 1-year high of $23.00. The stock has a market capitalization of $2.86 billion, a P/E ratio of -2.56, a P/E/G ratio of 1.27 and a beta of 1.33. The business has a fifty day moving average price of $19.99 and a 200-day moving average price of $19.63.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.